Extended TARPEYO® Treatment for IgA Nephropathy
This study is looking at whether taking TARPEYO® (a medication for IgA nephropathy) for a longer time is helpful and safe. You could join if you are an adult (18 or older) with IgA nephropathy (a kidney disease) that has been confirmed by a biopsy, and you have already completed 9 months of TARPEYO® 16 mg once daily. The main goal is to see if continuing TARPEYO® helps reduce protein in your urine (a sign of kidney damage) after 6 months compared to when you started the extended treatment. The study is currently unclear on its recruitment status and plans to enroll about 60 people.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It aims to enroll about 60 adult participants.
- What's involved
- You would take part in this study for about 19 months. This includes having urine tests, blood samples taken, and physical examinations.
- Compensation
- Not stated in the trial record.
- Follow-up
- After the treatment period, there will be a 3-month follow-up period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
At a glance
Conditions
Where it's being run
38 sites across 21 statesStudy leadership
- Krassimir Mitchev · STUDY_DIRECTOR · Calliditas Therapeutics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Ratio of Urine Protein to Creatine Ratio (UPCR) at 6 months compared to Baseline6 months
The outcome is measured as UPCR (based on 24-hour urine collection) at 6 months following the first dose of TARPEYO® trial treatment compared to study Baseline. Ratio being UPCR at 6 months in g/gram divided with UPCR at Baseline in g/gram.